10-Q: Nanophase Technologies Reports Strong Revenue Growth in Q3 2024 Driven by Solsence and Personal Care Ingredients

Nanophase Technologies Corporation saw a significant increase in revenue for the third quarter of 2024, primarily driven by its Solsence subsidiary and personal care ingredients segment.

Summary

• Nanophase Technologies Corporation reported a substantial increase in revenue for the third quarter of 2024, reaching $16.87 million, compared to $7.96 million in the same period of 2023.
• The company's product revenue also saw a significant jump, increasing to $16.79 million for the quarter, up from $7.75 million in the prior year.
• For the nine months ended September 30, 2024, total revenue was $39.78 million, compared to $29.29 million for the same period in 2023.
• Net income for the quarter was $3.045 million, a significant improvement from a net loss of $1.436 million in the third quarter of 2023.
• The company's net income per basic share was $0.04 for the quarter, compared to a loss of $0.03 per share in the same period last year.
• The increase in revenue was primarily driven by higher sales in the Solsence and Personal Care Ingredients product categories.
• The company's cost of revenue increased to $10.76 million for the quarter, up from $6.43 million in the same period of 2023, due to increased volume, manufacturing inefficiencies, and facility improvements.
• Research and development expenses decreased to $970,000 for the quarter, compared to $1.06 million in the same period of 2023.
• Selling, general, and administrative expenses increased to $1.93 million for the quarter, up from $1.70 million in the same period of 2023, due to an increase in the allowance for credit loss and increased employee-related costs.
• The company's cash balance at the end of the period was $2.93 million, compared to $1.72 million at the end of 2023.

Sentiment

Score: 8

Explanation: The document shows strong positive results with significant revenue growth and a return to profitability. However, there are some risks and challenges that need to be addressed, such as manufacturing inefficiencies and dependence on key customers.

Positives

• The company experienced a significant increase in revenue, driven by strong performance in the Solsence and Personal Care Ingredients segments.
• Nanophase achieved profitability in the third quarter of 2024, a notable turnaround from the loss in the same period of 2023.
• The company's cash position improved, indicating a stronger financial footing.
• The conversion of preferred stock to common stock has increased the number of outstanding shares, potentially improving liquidity.
• The company has extended the maturity of its loan agreements with Strandler, LLC and Beachcorp, LLC to October 1, 2025.

Negatives

• The cost of revenue increased significantly due to higher volume, manufacturing inefficiencies, and facility improvements.
• The company's advanced materials segment experienced lower sales.
• The company is dependent on a limited number of key customers, which could pose a risk if any of these customers reduce their orders.
• The company's loan agreements with Strandler, LLC and Beachcorp, LLC are set to expire on October 1, 2025, which could become an operating risk if they are not able to refinance or extend the maturity dates.

Risks

• The company's dependence on a limited number of key customers could lead to significant revenue loss if any of these customers reduce their orders.
• The terms of the supply agreements with BASF could trigger a requirement to sell equipment to that customer, resulting in a loss of revenue and potential capital outlays.
• The company's ability to obtain working capital when needed on acceptable terms is uncertain.
• The company's ability to obtain materials at costs they can pass through to customers is uncertain.
• There is uncertain demand for, and acceptance of, the company's Solsence products and advanced materials.
• The company's manufacturing capacity and product mix flexibility may not be sufficient to meet customer demand.
• The company has limited marketing experience, particularly with its Solsence products.
• Changes in development and distribution relationships could negatively impact the company.
• The company is dependent on patents and protection of proprietary information.
• The company's ability to maintain an appropriate electronic trading venue for its securities is uncertain.
• New governmental regulations, especially those focusing on nanomaterials, could be costly to comply with.
• Business interruptions due to unexpected events or public health crises could negatively impact the company.
• The company may become involved in litigation or other legal proceedings.
• The company's loan agreements with Strandler, LLC and Beachcorp, LLC are set to expire on October 1, 2025, which could become an operating risk if they are not able to refinance or extend the maturity dates.

Future Outlook

The company expects that as product revenue volume increases, its fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins. The company also expects capital spending relating to currently known capital needs for 2024 to be between $1 million and $2 million, to be funded by profit from operations, existing loans and lines of credit, and possible new debt financing.

Management Comments

• Management believes that the company's growth is happening now due to a confluence of its technology, market conditions that favor what it produces, and its expanded expertise in these areas.
• Management is focusing the company's combined business-, ingredient-, and product-development capabilities on products with unique performance in the skin health area.
• Management plans on expanding efforts in areas where they have proven they can deliver innovation and growth.
• Management believes that the company has developed technological advantages with respect to its APIs sold for use as ingredients, while its Solsence beauty science technologies lead to enhanced efficacy and aesthetics in its finished products.

Industry Context

The company's focus on skin health and beauty science aligns with the growing consumer demand for clean and inclusive beauty products. The company's vertical integration also helps to improve efficiency and avoid potential major supply chain challenges, which is a key concern in the current market.

Comparison to Industry Standards

• Nanophase's revenue growth in the third quarter of 2024 is significantly higher than the average growth rate for companies in the specialty chemicals and personal care ingredients sector, which typically see single-digit growth.
• The company's shift towards finished products through its Solsence subsidiary is similar to the strategy of companies like Amyris, which also develops and sells ingredients and finished products in the beauty and personal care space.
• The company's focus on mineral-based solutions aligns with the trend towards natural and sustainable ingredients, which is a growing market segment.
• Compared to companies like Croda International, which is a major player in the personal care ingredients market, Nanophase is still a smaller player but is showing strong growth potential.
• The company's gross margin is lower than some of its larger competitors, but this is expected to improve as the company scales up production and reduces manufacturing costs.

Related Party Transactions

• The company has loan agreements with Beachcorp, LLC and Strandler, LLC, which are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the company's common stock and is the brother of Ms. R. Janet Whitmore, a director of the company and the chair of the company's board of directors.
• The company issued 15,000 shares of Series X Preferred Stock to Strandler, LLC.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and increased share value.
• Employees may benefit from the company's growth and potential for increased compensation.
• Customers will benefit from the company's innovative products and services.
• Suppliers may benefit from increased orders and business opportunities.
• Creditors may benefit from the company's improved financial stability.

Next Steps

• The company plans to continue expanding efforts in areas where they have proven they can deliver innovation and growth.
• The company will focus on reducing controllable variable product manufacturing costs.
• The company will continue to adjust pricing to the extent supported by the markets they are in, and under any contract limitations they may have.
• The company expects capital spending relating to currently known capital needs for 2024 will be between $1 million and $2 million.

Key Dates

Keywords

Nanophase Technologies, Solsence, Personal Care Ingredients, Advanced Materials, Skin Health, Revenue Growth, Financial Results, Net Income, Preferred Stock, Common Stock, Manufacturing, Beauty Science, Cosmetics, Sunscreen, Active Pharmaceutical Ingredients